Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.76 |
| ▸ | ESRRA | P11474 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584478 | 0.86 | ESR1 (1.00) | ESR1ESR2ESRRAKDM4EALDH1A1 | |
| SCHEMBL14916690 | 0.82 | ESR1 (0.73) | ESR1ESR2ESRRAALDH1A1L3MBTL1 | |
| SCHEMBL2586078 | 0.81 | ESR1 (0.83) | ESR1ESR2ESRRAKDM4EALDH1A1 | |
| SCHEMBL2584396 | 0.81 | ESR1 (0.72) | ESR1ESR2ESRRAKDM4EALDH1A1 | |
| SCHEMBL2591935 | 0.81 | ESR1 (0.72) | ESR1ESR2ESRRA | |
| SCHEMBL2590217 | 0.78 | ESR2 (0.77) | ESR1ESR2ESRRAKDM4EALDH1A1 | |
| SCHEMBL13086952 | 0.75 | ESR2 (0.71) | ESR1ESR2ESRRAKDM4EALDH1A1 | |
| SCHEMBL2594093 | 0.72 | ESR2 (0.72) | ESR1ESR2ESRRAKDM4EALDH1A1 | |
| SCHEMBL14924140 | 0.70 | ESR2 (0.44) | ESR1ESR2ESRRAALDH1A1L3MBTL1 | |
| SCHEMBL1881456 | 0.70 | GRIA1 (0.47) | ESR1ESR2ESRRAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | claimed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | claimed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| EP-2647376-A1 | Nuclear receptor binding agents | Gtx, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | VA Long Beach Healthcare System (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2566330-A1 | NUCLEAR RECEPTOR BINDING AGENTS | Gtx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140228-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | ESR1 28/4885ESR2 4/4885ESRRA 3/4885 |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP3, NCOR1, NR3C2 | ESR1 375/4885ESR2 42/4885ESRRA 16/4885 |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | ESR1 168/4885ESR2 511/4885ESRRA 90/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | ESR1 63/4885ESR2 22/4885ESRRA 4/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | ESR1 145/4885ESR2 16/4885ESRRA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.